Joshua R. Trantum, Ph.D.

Josh is the President and Chief Investment Officer of CUREX Capital. Josh has spent his career in the life science industry in senior leadership roles of operating companies as well as on the investment side in equity research and portfolio management. Prior to co-founding CUREX in 2019, Josh was a buy-side research analyst covering the biotech and medtech sectors for a firm with approximately $3 billion in assets during his tenure. Josh has previously led pre-clinical drug development for a NASDAQ-listed biopharmaceutical company and co-founded a clinical stage company developing companion diagnostics for cancer immunotherapy. Earlier in his career, Josh worked as a senior biomedical engineer in the medical device industry where he oversaw the development and commercialization of devices that treat life-threatening cardiac arrhythmias. Josh attained his bachelor’s, master’s, and doctorate degrees in biomedical engineering from Vanderbilt University and his MBA from Emory University. He is co-author on papers published in peer-reviewed biomedical journals and is a co-inventor on multiple patents. Josh also currently holds a part-time adjunct appointment as Assistant Professor in the Department of Biomedical Engineering at Vanderbilt University.